“Takeda confirms that it is in discussions with the EC in relation to the future potential overlap in the area of inflammatory bowel disease between Takeda’s marketed product Entyvio (vedolizumab) and Shire’s pipeline compound SHP647, which is currently in Phase III clinical trials, and has proposed a remedy of a potential divestment of SHP647 and certain associated rights.”
also
Takeda and its chief executive officer, Christophe Weber, are reported to have a plan to deal with the debt. There are possible plans to sell Shire’s Xiidra eye treatment once the deal is completed, and possibly sell its Natpara, a drug used to control blood calcium levels. And it looks now like it will be selling SHP647.
(source: Biospace.com)
TAKEDA IS PLANNING TO BUY A HOUSE AND TO SUBSIDISE IT SELLS THE BASEMENT, THE GARAGE AND THE GARDEN.
also
Takeda and its chief executive officer, Christophe Weber, are reported to have a plan to deal with the debt. There are possible plans to sell Shire’s Xiidra eye treatment once the deal is completed, and possibly sell its Natpara, a drug used to control blood calcium levels. And it looks now like it will be selling SHP647.
(source: Biospace.com)
TAKEDA IS PLANNING TO BUY A HOUSE AND TO SUBSIDISE IT SELLS THE BASEMENT, THE GARAGE AND THE GARDEN.